Trial of Zinc and HIV Progression in Children

Harvard School of Public Health (HSPH)440 enrolled

Overview

To examine whether daily oral zinc supplementation to HIV-infected Tanzanian preschool children reduces diarrheal and respiratory morbidity, delays HIV disease progression, and improves growth.

The purpose of this study is to examine whether daily oral zinc supplementation to HIV-infected Tanzanian preschool children reduces diarrheal and respiratory morbidity, delays HIV disease progression, and improves growth.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

440

Conditions

HIV Infections

Interventions

ZincDIETARY_SUPPLEMENT

zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children \> 12 months.

Eligibility

Sex: ALLMin age: 6 WeeksMax age: 60 Months

Medical Language ↔ Plain English

Inclusion Criteria: * HIV Infected Children under 60 months of age presenting at HIV treatment clinics in Dar es Salaam, Tanzania Exclusion Criteria: Eligible for ART: CD4 cell counts \< 20% or above pediatric clinical stage of HIV disease 3 according to WHO staging system. Severe acute malnutrition; Major congenital malformations

Locations (1)

Muhimbili University College of Health Sciences

Dar es Salaam, Tanzania

Outcomes

Primary Outcomes

Morbidity from respiratory and diarrheal infections, HIV disease progression

Time frame: every 4 to 6 months until the end of follow-up

Secondary Outcomes

growth in height and weight

Time frame: every 4 to 6 months until the end of follow-up

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.